Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Otonomy Inc (OTIC)

Otonomy Inc (OTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,...

AGTC : 3.11 (unch)
OTIC : 2.20 (-1.34%)
Otonomy to Present at the Cantor Global Healthcare Conference

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive...

OTIC : 2.20 (-1.34%)
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413,...

OTIC : 2.20 (-1.34%)
Otonomy: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Otonomy Inc. (OTIC) on Thursday reported a loss of $11.7 million in its second quarter.

OTIC : 2.20 (-1.34%)
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update

-- Current capital funds operations into 2021

OTIC : 2.20 (-1.34%)
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter...

OTIC : 2.20 (-1.34%)
Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates

Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

OTIC : 2.20 (-1.34%)
Otonomy: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Otonomy Inc. (OTIC) on Monday reported a loss of $12 million in its first quarter.

OTIC : 2.20 (-1.34%)
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

-- OTIPRIO co-promotion agreement completed with Glenmark Therapeutics

OTIC : 2.20 (-1.34%)
Otonomy, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Otonomy, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 6, 2019 at 4:30 PM Eastern Time.

OTIC : 2.20 (-1.34%)
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication

Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., today announced a co-promotion agreement with Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to...

OTIC : 2.20 (-1.34%)
Otonomy Announces OTIPRIO(R) Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark...

OTIC : 2.20 (-1.34%)
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the company will host one-on-one meetings with investors...

OTIC : 2.20 (-1.34%)
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter...

OTIC : 2.20 (-1.34%)
Report: Developing Opportunities within Noble, Harris, Jazz Pharmaceuticals, Teradata, Abeona Therapeutics, and Otonomy -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Noble Corporation (NYSE:NE),...

NE : 1.28 (-1.54%)
HRS : 189.13 (-0.17%)
JAZZ : 120.04 (-0.90%)
TDC : 28.70 (-1.34%)
ABEO : 2.16 (-4.42%)
OTIC : 2.20 (-1.34%)
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313,...

OTIC : 2.20 (-1.34%)
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

OTIC : 2.20 (-1.34%)
ATNM : 0.21 (+5.00%)
ALPN : 2.72 (+0.74%)
MTEM : 7.76 (+5.01%)
TCDA : 35.43 (+1.43%)
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

ATNM : 0.21 (+5.00%)
OTIC : 2.20 (-1.34%)
KALV : 11.59 (-3.90%)
ACRX : 2.20 (-0.45%)
MTEM : 7.76 (+5.01%)
ALPN : 2.72 (+0.74%)
TCDA : 35.43 (+1.43%)
Will Otonomy Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Otonomy.

OTIC : 2.20 (-1.34%)
Otonomy to Participate in Two Upcoming Investor Conferences

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive...

OTIC : 2.20 (-1.34%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +5.17 , AIZ +0.14 , SBAC +5.76 , SO +0.10 , WELL +1.08
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar